Methods for treating age-related macular degeneration
AssigneeNovartis AG
InventorsMargarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
Life of this patent
Estimating the term…
Abstract
A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
Claims20
-10. (canceled)
A method for inhibiting choroidal neovascularization (CNV) in a patient in need thereof, the method comprising administering an anti-VEGF antagonist to the patient at monthly intervals for three doses, followed by administering to the patient one dose every 12 weeks or every 8 weeks, wherein each dose of the anti-VEGF antagonist is at least 3 mg, wherein the anti-VEGF antagonist comprises a heavy chain variable domain having the sequence as set forth in SEQ ID NO:
- 1 and a light chain variable domain having the sequence as set forth in SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.